Back to top
more

Athersys, Inc. (ATHX)

(Delayed Data from NSDQ)

$1.55 USD

1.55
403,009

+0.04 (2.65%)

Updated May 3, 2019 04:00 PM ET

After-Market: $1.55 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Athersys (ATHX) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

What Makes Athersys (ATHX) a New Buy Stock

by Zacks Equity Research

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study

by Zacks Equity Research

Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.

Athersys (ATHX) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Athersys (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%

by Zacks Equity Research

Audentes Therapeutics (BOLD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Alnylam Files Clinical Trial Application for ALN-AAT02 in UK

by Zacks Equity Research

Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.

    Amgen Gets FDA Nod for Once-Weekly Regimen of Kyprolis Combo

    by Zacks Equity Research

    Amgen (AMGN) gains an FDA approval for its sNDA with respect to a once-weekly dosing option of its multiple myeloma drug Kyprolis (70 mg/m2) combined with dexamethasone (Kd).

      Medicines Company to Continue Inclisiran Studies as Planned

      by Zacks Equity Research

      The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.

        The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

        by Zacks Equity Research

        The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion

          Nitish Marwah headshot

          IPOs and Foreign Investment Propel Biotech: 4 Top Picks

          by Nitish Marwah

          A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.

            Is Athersys (ATHX) Stock Outpacing Its Medical Peers This Year?

            by Zacks Equity Research

            Is (ATHX) Outperforming Other Medical Stocks This Year?

              Ekta Bagri headshot

              4 Biotech Stocks to Bet on in the Second Half of 2018

              by Ekta Bagri

              While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.

                Athersys Enters Oversold Territory

                by Zacks Equity Research

                Athersys Enters Oversold Territory

                  Top Ranked Momentum Stocks to Buy for June 12th

                  by Zacks Equity Research

                  Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 12th:

                    The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                      Gourav Kanti Bagchi headshot

                      "Right To Try" Brings Good News for Biotech Sector: 5 Picks

                      by Gourav Kanti Bagchi

                      Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.

                        Kinjel Shah headshot

                        5 Biotech Stocks to Boost Your Portfolio's Health This Year

                        by Kinjel Shah

                        Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.

                          BioMarin's Palynziq Gets FDA Approval for Phenylketonuria

                          by Zacks Equity Research

                          BioMarin's (BMRN) enzyme therapy, Palynziq (pegvaliase) gets approval for the treatment of phenylketonuria in adult patients.

                            INSYS Gets Negative FDA Recommendation for Pain Candidate

                            by Zacks Equity Research

                            INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

                              Moving Average Crossover Alert: Athersys, Inc. (ATHX)

                              by Zacks Equity Research

                              Moving Average Crossover Alert: Athersys, Inc. (ATHX)

                                Athersys (ATHX) in Focus: Stock Moves 7.2% Higher

                                by Zacks Equity Research

                                Athersys (ATHX) shares rose more than 7% in the last trading session, amid huge volumes.

                                  Athersys (ATHX) in Focus: Stock Moves 10.22% Higher

                                  by Zacks Equity Research

                                  Athersys (ATHX) was a big mover last session, as the company saw its shares rise more than 10% on the day.

                                    Why Athersys, Inc. (ATHX) Could Be Positioned for a Surge

                                    by Zacks Equity Research

                                    Athersys, Inc. (ATHX) seems to Be Positioned for a Surge on the back of its favorable zacks rank and solid estimate revisions.

                                      Can the Rally in Athersys (ATHX) Shares Continue?

                                      by Zacks Equity Research

                                      Athersys, Inc. (ATHX) has been on the move lately as the stock has risen by 62.4% in the past four weeks, and it is currently trading well above its 20-Day SMA